'Breakthrough' diabetes drug cut kidney and heart disease deaths by a third, trial shows
A breakthrough treatment could help protect hundreds of millions of people from the “21st century epidemic” of deadly diabetic kidney disease, a major trial has found.
Research from Australia and the UK has shown that a once-a-day blood sugar lowering drug, canagliflozin, reduced cases of kidney failure and death by a third in diabetic patients.
There are nearly five million UK diabetics and diabetic kidney disease costs the NHS as much as £927m a year according to researchers . However there have been no new treatments for nearly two decades.
“There are more than 400 million people with diabetes worldwide, around 40 per cent of these people will get kidney disease,” said the study’s lead author Professor Vlado Perkovic, executive director of the George Institute for Global Health.
“Once they’ve got kidney disease, they’re at very high risk of kidney failure, heart attack, stroke, and of death.”
Research from Australia and the UK has shown that a once-a-day blood sugar lowering drug, canagliflozin, reduced cases of kidney failure and death by a third in diabetic patients.
There are nearly five million UK diabetics and diabetic kidney disease costs the NHS as much as £927m a year according to researchers . However there have been no new treatments for nearly two decades.
“There are more than 400 million people with diabetes worldwide, around 40 per cent of these people will get kidney disease,” said the study’s lead author Professor Vlado Perkovic, executive director of the George Institute for Global Health.
“Once they’ve got kidney disease, they’re at very high risk of kidney failure, heart attack, stroke, and of death.”
No comments:
Post a Comment